SLOUGH, United Kingdom and RICHMOND, Virginia, Sept. 24, 2020 /PRNewswire/ — Indivior PLC (LON: INDV) today announced that it is taking organizational and cost actions to better align its capabilities and resources with the Group’s strategic priorities. These actions further consider Indivior’s strategy and are intended to enhance the Group’s commercial and R&D focus on the highest value opportunities, protect the Group’s financial and operational flexibility in response to ongoing challenges posed by the COVID-19 pandemic and support the Group’s long-term growth ambitions.
Key actions Indivior is taking include:
- Reorganizing and reinvesting in the U.S. commercial function in-line with the continued penetration and growth of SUBLOCADE® (buprenorphine extended-release) Injection in the Organized Health System (OHS) channel and to facilitate expansion of PERSERIS® (risperidone) extended release injection into the OHS channel. This includes hiring and redirecting some employees to further our progress in this channel.
- Further focusing of